Cell Line-Derived Syngeneic Models
Among various model systems, cell line-derived syngeneic models have emerged as powerful tools for studying rare diseases. These models, offered by cutting-edge companies like our company, provide a unique opportunity to investigate the intricate aspects of rare diseases and accelerate the development of effective rare disease drugs. As a leading company, we are committed to providing state-of-the-art cell line-derived syngeneic model development services for rare disease research.
What is Cell Line-Derived Syngeneic Model?
Cell line-derived syngeneic models, also called cell line-derived allograft models, are transplantation models that involve injecting tumor cells derived from a specific genetic background into a recipient mouse of the same genetic background. Compared with the CDX model, the murine tumor cell line transplantation mouse model retains the intact mouse immune system, which can be used to study the performance of cancer immunotherapy in the presence of a functional immune system. These models faithfully recapitulate the tumor microenvironment and immune response associated with rare diseases, making them invaluable for studying disease progression and evaluating therapeutic interventions.
Fig.1 Types and generation of cancer models. (Bareham, B., et al., 2021) Advantages of Cell Line-Derived Syngeneic Models
Recapitulation of Disease Characteristics
Cell line-derived syngeneic models faithfully recapitulate the key disease characteristics of rare diseases. By carefully selecting a cell line that represents the genetic and phenotypic features of the disease, researchers can accurately study disease progression, molecular pathways, and therapeutic responses within an in vivo setting.
High Reproducibility and Scalability
Cell line-derived syngeneic models offer high reproducibility and scalability, allowing for consistent and standardized experiments. Unlike patient-derived xenograft models, which can exhibit inter-individual variability, cell line-derived models provide a renewable resource with consistent genetic and phenotypic characteristics.
Our Services
Providing comprehensive support throughout the research process, including cell line-derived syngeneic model selection, experimental design, data analysis, drug safety evaluation, and pharmacokinetics research. Assist researchers at every stage of their rare disease studies by offering guidance, technical expertise, and customized solutions to ensure successful research endeavors.
Why Choose Us?
- Provide professional technical support
- Utilize the extensive experience gained from successful new drug development cases
- Ensure timely project reporting and offer after-sales service
- Implement a fast and cost-efficient workflow
- Offer a one-stop platform with an experienced technical team
- Execute careful design and maintain transparency in the operation process
With a team of highly skilled scientists and researchers, our company is at the forefront of rare disease research. We have accumulated extensive knowledge and expertise over many years, allowing us to provide comprehensive services in developing cell line-derived syngeneic models. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
Reference
- Bareham, B., et al. "Modeling human tumor-immune environments in vivo for the preclinical assessment of immunotherapies." Cancer Immunology, Immunotherapy 70 (2021): 2737-2750.
| Cell Line | Cancer Type | Organism | Animal Model |
|---|---|---|---|
| J82 | Bladder | Homo sapiens | M-NSG |
| MB-49 | Bladder | Mus musculus | |
| RT112 | Bladder | Homo sapiens | |
| RT112-Luc | Bladder | Homo sapiens | |
| RT4 | Bladder | Homo sapiens | |
| BT-474 | Breast | Homo sapiens | M-NSG |
| EMT-6-hPD-L1 | Breast | Mus musculus | BALB/c |
| EMT6 | Breast | Mus musculus | BALB/c |
| EMT6-hHER2-Luc | Breast | Mus musculus | |
| EMT6-hMSLN | Breast | Mus musculus | |
| EMT6-hNECTIN4 | Breast | Mus musculus | |
| EMT6-Luc | Breast | Mus musculus | BALB/c |
| EMT6-OVA | Breast | Mus musculus | |
| EMT6-Stc1-KO | Breast | Mus musculus | |
| HCC1395 | Breast | Homo sapiens | |
| HCC1428 | Breast | Homo sapiens | |
| HCC1806 | Breast | Homo sapiens | |
| HCC1937 | Breast | Homo sapiens | M-NSG |
| HCC1954 | Breast | Homo sapiens | |
| HCC70 | Breast | Homo sapiens |
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.